Holen Sie sich die Stockscreener-App
19.61
0.31%
0.06
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK sells Iridium stock, buys Nurix on Wednesday - Investing.com
What insider trading reveals about Nurix Therapeutics Inc stockMarket Activity Report & Risk Controlled Daily Plans - BỘ NỘI VỤ
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
NRIX: Mizuho Raises Price Target, Maintains Outperform Rating | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 at Mizuho - MarketBeat
Nurix stock price target raised to $31 from $28 at H.C. Wainwright - Investing.com UK
NRIX: HC Wainwright & Co. Raises Price Target for Nurix Therapeu - GuruFocus
Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 5.4%Here's Why - MarketBeat
NRIX Analyst Rating Update: BTIG Raises Price Target | NRIX Stoc - GuruFocus
Nurix (NRIX) soars 18.7% on encouraging blood cancer treatment trial - MSN
Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Insider Monkey
NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia - TradingView
Nurix Therapeutics Presents New Clinical Data at ASH Annual Meeting - TradingView
Nurix reports 75% response rate for bexobrutideg in WM patients By Investing.com - Investing.com Australia
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpTime to Buy? - MarketBeat
Needham Reiterates Nurix Therapeutics (NRIX) Buy Recommendation - Nasdaq
Could This Biotech, Up 35%, Have The Next Dupixent? - Investor's Business Daily
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg in Waldenström Macroglobulinemia at the 67th American Society of Hematology Annual Meeting and Exposition - Investing News Network
Nurix reports 75% response rate for bexobrutideg in WM patients - Investing.com
NRIX Clinical Trial Data Highlights Promising Results for Bexobr - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports 75% Objective Response Rate for Bexobrutideg in Heavily Pre-treated Waldenström Macroglobulinemia Patients at ASH Annual Meeting - Quiver Quantitative
Nurix Therapeutics presents new data from the phase 1 trial of bexobrutideg in Waldenström macroglobulinemia at the 67th American Society of Hematology annual meeting and exposition - marketscreener.com
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - Yahoo Finance
Nurix Therapeutics (NRIX): Analyst Reiterates Buy Rating, Mainta - GuruFocus
NRIX Shows Promising Results in Phase 1a/1b Clinical Trial for B - GuruFocus
Bollard Group LLC Makes New $1.40 Million Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix reports 83% response rate for bexobrutideg in CLL patients - Investing.com
Nurix Therapeutics Reports Promising Phase 1a/1b Clinical Data for Bexobrutideg in Patients with Relapsed or Refractory CLL, Showcasing 83% Objective Response Rate and 22.1 Months Median Progression-Free Survival - Quiver Quantitative
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (AS - Stock Titan
Affinity Asset Advisors LLC Increases Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Is Nurix Therapeutics Inc. stock positioned for long term growthPortfolio Risk Summary & Low Drawdown Trading Techniques - Newser
In the Wake of Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Latest US$86m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
Nurix Therapeutics (NRIX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast - Yahoo Finance
What is the fair value of Nurix Therapeutics Inc. stock now - Newser
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is the Upcoming NX-5948 Clinical Data Update Shaping the Investment Case for Nurix Therapeutics (NRIX)? - simplywall.st
Nurix to host webcast on bexobrutideg clinical data next week By Investing.com - Investing.com Canada
Nurix to host webcast on bexobrutideg clinical data next week - Investing.com
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - The Manila Times
Nurix Therapeutics to Host Webcast on Clinical Data for Bexobrutideg in CLL and WM on December 8, 2025 - Quiver Quantitative
Nurix Therapeutics (Nasdaq: NRIX) to host Dec. 8 webcast on Phase 1 bexobrutideg CLL data - Stock Titan
Geode Capital Management LLC Purchases 157,592 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX Shares Sold by Intech Investment Management LLC - MarketBeat
(NRIX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Transcript : Nurix Therapeutics, Inc. Presents at Stifel 2025 Healthcare Conference, Nov-13-2025 09 - marketscreener.com
Rhenman & Partners Asset Management AB Has $2.11 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Is Available Finance Limited a Top Growth Stock to Watch in YEAR - earlytimes.in
Why Nurix Therapeutics Inc. stock could outperform in 2025Weekly Trading Summary & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
280,000 Shares in Nurix Therapeutics, Inc. $NRIX Purchased by Handelsbanken Fonder AB - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at Truist Financial - MarketBeat
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - Investing News Network
Nurix Therapeutics (Nasdaq: NRIX) fireside chat at Piper Sandler 37th conference - Stock Titan
[Form 4] Nurix Therapeutics, Inc. Insider Trading Activity - Stock Titan
Nurix Therapeutics Chief Legal Officer Sells Shares - TradingView
Officer Ring Files To Sell 37,600 Of Nurix Therapeutics Inc [NRIX] - TradingView
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):